Choice Cancer Care has sold a majority interest to Cancer Treatment Centers America
October 2018 — The shareholder of Choice Cancer Care has sold a majority interest to Cancer Treatment Centers America. Financial details have not been disclosed.
Choice Cancer Care (CCC) is a QOPI certified medical and radiation oncology practice with six locations across North Texas. It is among the busiest practices in the country for brachytherapy, a prostate seed implant therapy.
Cancer Treatment Centers of America (CTCA) operates cancer treatment hospitals in Atlanta, Chicago, Philadelphia, Phoenix, and Tulsa and outpatient facilities in Chicago, Phoenix, and Scottsdale. With over 160 MDs, the company is highly regarded for its patient-centered philosophy, genomic and state-of-the-art technologies, wide array of precision treatment options, and comprehensive expertise across most cancer types.
Our role in the transaction
Oaklins' team in Dallas contacted several strategic and private equity parties with a history of acquiring specialty practices. Typical metrics to value the business did not provide a profitable exit strategy. The team succeeded in cultivating good interest with a financially strong acquiror to expand its presence into North Texas and negotiated a highly profitable exit for the shareholder, including substantial cash, strong retention incentives, and continued ownership to monetize expansion efforts into underserved markets.
Talk to the deal team
Bryan Livingston
Oaklins Capital Alliance
Related deals
UKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Learn moreMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Learn moreQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Learn more